In fiscal year 2025, KANGSTEM BIOTECH (217730) reported revenue of 3.6 billion KRW.
Income Statement
| Year | Revenue | Op Profit | Net Income | Source |
|---|
| 2025 | 3.6 billion KRW | -17.7 billion KRW | -10.5 billion KRW | [source] |
| 2024 | 7.7 billion KRW | -14.8 billion KRW | -8.0 billion KRW | [source] |
| 2023 | 12.7 billion KRW | -22.8 billion KRW | -23.2 billion KRW | [source] |
| 2022 | 16.3 billion KRW | -20.6 billion KRW | -20.2 billion KRW | [source] |
| 2021 | 12.4 billion KRW | -22.7 billion KRW | -21.8 billion KRW | [source] |
Balance Sheet
| Year | Total Assets | Total Liabilities | Total Equity | Source |
|---|
| 2025 | 70.6 billion KRW | 10.9 billion KRW | 59.7 billion KRW | [source] |
| 2024 | 56.0 billion KRW | 12.8 billion KRW | 43.2 billion KRW | [source] |
| 2023 | 71.4 billion KRW | 18.2 billion KRW | 53.2 billion KRW | [source] |
| 2022 | 68.9 billion KRW | 17.4 billion KRW | 51.4 billion KRW | [source] |
| 2021 | 90.2 billion KRW | 20.0 billion KRW | 70.1 billion KRW | [source] |
Cash Flow
| Year | Operating | Investing | Financing | Source |
|---|
| 2025 | -11.7 billion KRW | -24.3 billion KRW | 35.2 billion KRW | [source] |
| 2024 | — | — | — | [source] |
| 2023 | -16.5 billion KRW | -2.3 billion KRW | 20.0 billion KRW | [source] |
| 2022 | -18.9 billion KRW | 16.2 billion KRW | -231 million KRW | [source] |
| 2021 | -17.0 billion KRW | -24.8 billion KRW | 39.3 billion KRW | [source] |
Cash flow figures for the relevant year were not collected.
